Ristabbs 0.5, 1 & 2 0.5 mg; 1 mg, 2 mg Orally Dispersible Tablets
PDF Leaflet Revision Date: 19 June 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of schizophrenia, mania in bipolar disorder, and conduct disorders in children.
Dosage (summary)
Adults: Start at 2 mg/day, increase to 4 mg/day on day 2; maintenance 4-8 mg/day. Elderly/Renal/Hepatic: Start at 0.5 mg twice daily.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Use only if benefits outweigh risks; contraindicated in breastfeeding.
Key Drug Interactions
- CYP2D6 inhibitors
- CYP3A4 inhibitors
- Levodopa
Contraindications
- Hypersensitivity to risperidone
- Children under 5 years
- Parkinsonu2019s disease
- Lewy Body Dementia
Common side effects
- Hyperprolactinaemia
- Weight gain
- Sedation
- Extrapyramidal symptoms
Counselling Points
- Monitor for weight gain
- Avoid dehydration
- Caution with driving and machinery
Serious warnings
- Increased mortality in elderly patients with dementia
- Neuroleptic Malignant Syndrome
- Tardive Dyskinesia
Important Disclaimer
The Ristabbs 0.5, 1 & 2 0.5 mg; 1 mg, 2 mg Orally Dispersible Tablets professional information leaflet below is the property of Innovata Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
